International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 • Website: www.ijfmr.com • Email: editor@ijfmr.com

Pharmacovigilance Review of Acyclovir: Mechanisms, Safety Profile, and Clinical Considerations

Pallavi Prabhakar Patil[1], Umme Roman Shaikh[2]

[1]Student, Department of Pharmacy
[2]Assistant Professor, Department of Pharmacy
[1,2]Sayali Charitable Trust's College of Pharmacy, Chhatrapati Sambhajinagar, Maharashtra, India

Abstract:
Acyclovir (ACV) is a guanine nucleoside analogue widely used for the treatment and prophylaxis of herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. Its mechanism of action involves selective phosphorylation by viral thymidine kinase, leading to inhibition of viral DNA polymerase and termination of viral DNA replication. While acyclovir exhibits a favorable safety profile, pharmacovigilance data have identified significant adverse drug reactions (ADRs), including nephrotoxicity due to crystalluria, neurotoxicity in renally impaired or elderly patients, and rare hematologic or severe cutaneous reactions. This review summarizes the pharmacokinetics, therapeutic applications, ADR patterns, drug–drug interactions, and considerations in special populations. Emphasis is placed on clinical interpretation, risk factors, dose adjustments, and strategies for early detection and prevention of ADRs. The review also highlights comparative safety with related antivirals and the role of post-marketing surveillance in optimizing patient safety.
Clinical Relevance: Understanding acyclovir pharmacovigilance is critical to prevent severe ADRs, guide safe dosing, and improve therapeutic outcomes in both immunocompetent and immunocompromised patients.

Keywords: Acyclovir, Pharmacovigilance, Adverse drug reactions (ADRs), Nephrotoxicity, Neurotoxicity, Herpes simplex virus (HSV), Varicella-zoster virus (VZV), Drug–drug interactions, Special populations, Post-marketing surveillance.

1. Introduction

Acyclovir (ACV) is a synthetic guanine nucleoside analogue that has been used since the late 1970s for the treatment and prophylaxis of herpes simplex virus (HSV) types 1 and 2, varicella-zoster virus (VZV), and less commonly, Epstein-Barr virus (EBV) infections [1], [2]. Its clinical efficacy stems from selective antiviral activity that preferentially targets infected cells while sparing uninfected host cells, making it a cornerstone therapy for both immunocompetent and immunocompromised patients. Pharmacovigilance—the science and activities related to detecting, assessing, understanding, and preventing adverse drug reactions (ADRs) or any other drug-related problems—is crucial for acyclovir due to its widespread use. Although generally well-tolerated, ADRs such as nephrotoxicity, neurotoxicity, hematologic reactions, and rare severe cutaneous reactions have been reported, particularly in populations with renal impairment, advanced age, or prolonged intravenous therapy [3], [4]. The purpose of this review is to provide a comprehensive analysis of acyclovir pharmacology, therapeutic applications, pharmacokinetics, ADR patterns, drug interactions, special population considerations, and pharmacovigilance insights, highlighting strategies to optimize safety and clinical outcomes



.

Clinical Interpretation:
Acyclovir's safety profile is favorable, but vigilant monitoring in at-risk populations is essential to prevent potentially severe adverse events. Proper hydration, renal function assessment, dose adjustment, and awareness of early signs of toxicity are critical for safe clinical use.

2. Mechanism of Action

Acyclovir (ACV) is a synthetic **guanine nucleoside analogue** that exhibits selective antiviral activity by targeting viral DNA replication in infected cells. Its action depends on three critical steps: activation, inhibition of viral DNA synthesis, and clinical selectivity.

2.1 Activation

- **Viral Thymidine Kinase (TK):** In cells infected by HSV or VZV, viral thymidine kinase phosphorylates acyclovir to **acyclovir monophosphate (ACV-MP)**. This activation step is largely responsible for acyclovir's selectivity because uninfected host cells phosphorylate ACV very inefficiently [5], [6].
- **Host Cellular Kinases:** Cellular kinases convert ACV-MP to **acyclovir diphosphate (ACV-DP)** and finally to **acyclovir triphosphate (ACV-TP)**, which is the pharmacologically active form [7].

2.2 Inhibition of Viral DNA Synthesis

Once phosphorylated, ACV-TP inhibits viral replication through:

- **Competitive Inhibition:** ACV-TP competes with deoxyguanosine triphosphate (dGTP) for incorporation into viral DNA by **viral DNA polymerase**, reducing viral DNA synthesis.

- **Chain Termination:** ACV-TP lacks a 3′-hydroxyl group; its incorporation into viral DNA prevents further elongation, causing premature termination of the DNA strand [5], [8].

2.3 Selectivity and Clinical Relevance

The dependence on viral TK ensures that only **infected cells activate the drug**, which minimizes host cell toxicity. This selective mechanism explains acyclovir's **favorable therapeutic index** and widespread clinical use [6], [9].

2.4 Resistance Mechanisms

Although rare in immunocompetent patients, resistance can occur, particularly in immunocompromised individuals with prolonged therapy. Mechanisms include:

- **Viral TK mutations:** Loss or alteration of thymidine kinase activity prevents ACV phosphorylation, causing drug inactivity. This accounts for ~95% of resistance cases [10].
- **Viral DNA polymerase mutations:** Reduced binding of ACV-TP to viral polymerase decreases antiviral efficacy.
- Clinically, resistance may present as persistent mucocutaneous lesions or recurrent infections, often requiring alternative therapy such as **foscarnet** or **cidofovir** [10], [11].

Clinical Interpretation:

Clinicians should monitor immunocompromised patients for treatment failure and consider resistance testing. Dose adjustments and renal monitoring are essential in patients with impaired kidney function to prevent toxicity.

2. Mechanism of Action



Acyclovir (ACV) is a synthetic **guanine nucleoside analogue** that exhibits selective antiviral activity by targeting viral DNA replication in infected cells. Its action depends on three critical steps: activation, inhibition of viral DNA synthesis, and clinical selectivity.

2.1 Activation

- **Viral Thymidine Kinase (TK):** In cells infected by HSV or VZV, viral thymidine kinase phosphorylates acyclovir to **acyclovir monophosphate (ACV-MP)**. This activation step is largely responsible for acyclovir's selectivity because uninfected host cells phosphorylate ACV very inefficiently [5], [6].
- **Host Cellular Kinases:** Cellular kinases convert ACV-MP to **acyclovir diphosphate (ACV-DP)** and finally to **acyclovir triphosphate (ACV-TP)**, which is the pharmacologically active form [7].

2.2 Inhibition of Viral DNA Synthesis

Once phosphorylated, ACV-TP inhibits viral replication through:

- **Competitive Inhibition:** ACV-TP competes with deoxyguanosine triphosphate (dGTP) for incorporation into viral DNA by **viral DNA polymerase**, reducing viral DNA synthesis.
- **Chain Termination:** ACV-TP lacks a 3′-hydroxyl group; its incorporation into viral DNA prevents further elongation, causing premature termination of the DNA strand [5], [8].

2.3 Selectivity and Clinical Relevance

The dependence on viral TK ensures that only **infected cells activate the drug**, which minimizes host cell toxicity. This selective mechanism explains acyclovir's **favorable therapeutic index** and widespread clinical use [6], [9].

2.4 Resistance Mechanisms

Although rare in immunocompetent patients, resistance can occur, particularly in immunocompromised individuals with prolonged therapy. Mechanisms include:

- **Viral TK mutations:** Loss or alteration of thymidine kinase activity prevents ACV phosphorylation, causing drug inactivity. This accounts for ~95% of resistance cases [10].
- **Viral DNA polymerase mutations:** Reduced binding of ACV-TP to viral polymerase decreases antiviral efficacy.
- Clinically, resistance may present as persistent mucocutaneous lesions or recurrent infections, often requiring alternative therapy such as **foscarnet** or **cidofovir** [10], [11].

Clinical Interpretation:

Clinicians should monitor immunocompromised patients for treatment failure and consider resistance testing. Dose adjustments and renal monitoring are essential in patients with impaired kidney function to prevent toxicity.

3. Therapeutic Uses

Acyclovir (ACV) is a first-line antiviral agent for a range of herpesvirus infections due to its efficacy and safety profile. Its therapeutic applications include:

3.1 Herpes Simplex Virus (HSV) Infections

- **Primary Genital and Oral Herpes:** ACV reduces symptom duration, viral shedding, and recurrence frequency. Oral and intravenous formulations are used depending on severity [12], [13].
- **HSV Encephalitis:** Intravenous ACV is the gold standard for HSV encephalitis, reducing mortality and neurological sequelae when administered early [14].
- **Neonatal HSV:** High-dose intravenous ACV is critical for treating neonatal HSV infections to prevent systemic complications and improve survival [15].

3.2 Varicella-Zoster Virus (VZV) Infections

- **Shingles (Herpes Zoster):** ACV shortens lesion healing time, reduces acute pain, and lowers the incidence of postherpetic neuralgia in adults and children [16], [17].
- **Prophylaxis:** Immunocompromised patients, including organ transplant recipients, benefit from prophylactic ACV to prevent VZV reactivation [18].



3.3 Other Clinical Uses

- **Immunocompromised Hosts:** ACV prevents or treats mucocutaneous HSV infections, disseminated VZV, and EBV complications in immunocompromised patients such as HIV-positive individuals, transplant recipients, or chemotherapy patients [19], [20].
- **Suppressive Therapy:** Long-term low-dose ACV reduces recurrence frequency in patients with frequent HSV outbreaks, improving quality of life [21].
- **Clinical Interpretation:**
- While ACV effectively manages acute infections and prevents recurrences, clinicians should remember that it **does not eradicate latent virus**. In immunocompromised patients or those with prolonged therapy, **resistance monitoring and dose adjustments** may be necessary. Early initiation of therapy is critical for maximum benefit, particularly in CNS infections and neonatal HSV.

4. Adverse Drug Reactions (ADRs)

Acyclovir is generally well-tolerated; however, post-marketing pharmacovigilance data and clinical studies have identified a spectrum of adverse drug reactions, ranging from mild gastrointestinal effects to severe renal or neurological complications. Understanding these ADRs is critical for **risk assessment, early detection, and management**.

4.1 Renal Toxicity

- **Crystalluria and Acute Kidney Injury (AKI):** High-dose intravenous acyclovir or inadequate hydration can lead to crystal formation in renal tubules, resulting in obstructive nephropathy. Clinically, patients may present with elevated serum creatinine, reduced urine output, or flank pain [22], [23].
- **Risk Factors:** Pre-existing renal impairment, elderly age, concomitant nephrotoxic drugs (e.g., aminoglycosides, NSAIDs), and rapid IV infusion increase the risk.
- **Management:** Adequate hydration, slow IV infusion, dose adjustment based on creatinine clearance, and monitoring renal function are essential preventive measures [24].

4.2 Neurotoxicity

- **Manifestations:** Headache, confusion, agitation, hallucinations, tremors, myoclonus, and rarely seizures may occur, particularly in patients with renal dysfunction [25], [26].
- **Mechanism:** Accumulation of ACV and its metabolites in the CNS due to impaired renal clearance contributes to neurotoxicity.
- **Clinical Management:** Dose reduction, discontinuation of ACV if severe, and supportive therapy. Monitoring serum creatinine and neurologic status is recommended in high-risk populations [26].

4.3 Hematologic and Dermatologic Reactions

- **Hematologic:** Rare thrombocytopenia, leukopenia, or hemolytic anemia have been reported, mostly in immunocompromised patients [27].
- **Dermatologic:** Rash, pruritus, or very rarely Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) may occur [28].
- **Clinical Interpretation:** These events are uncommon but require immediate discontinuation of therapy and supportive management when severe.



4.4 Gastrointestinal and Other Minor ADRs

- Nausea, vomiting, diarrhea, and headache are the most frequently reported mild adverse effects [29].
- Phlebitis at IV injection sites may occur and can be minimized by slow infusion and rotating IV sites.

Clinical Interpretation:

ADRs are generally dose- and renal function-dependent. Early identification and preventive strategies, such as hydration and renal monitoring, significantly reduce serious complications. Pharmacovigilance data suggest that intravenous therapy in at-risk populations should always be accompanied by **renal function assessment** and **neurological monitoring**.

5. Pharmacokinetics

Acyclovir exhibits well-characterized pharmacokinetics, with properties that support its clinical effectiveness and influence dosing strategies in special populations.

5.1 Absorption

- **Oral Administration:** Acyclovir has moderate oral bioavailability (~10–20%), which limits systemic exposure compared to intravenous administration. Peak plasma concentrations occur 1.5–2 hours post-ingestion [30].
- **Influence of Food:** Food does not significantly affect absorption, making it suitable for administration with or without meals [30].



5.2 Distribution

- Acyclovir is **widely distributed** in body fluids and tissues, including saliva, cerebrospinal fluid (CSF), and skin lesions, which supports its efficacy against mucocutaneous and CNS infections [31], [32].
- **Plasma Protein Binding:** Approximately 9–33%, relatively low, allowing efficient tissue penetration [32].

5.3 Metabolism

- Minimal hepatic metabolism occurs; acyclovir is largely excreted unchanged. Minor metabolism produces **9-carboxymethoxymethylguanine (CMMG)**, which may accumulate in renal impairment and contribute to neurotoxicity [33].

5.4 Excretion

- Primarily **renal clearance** via glomerular filtration and tubular secretion. Half-life in patients with normal renal function is 2.5–3.3 hours, but it is significantly prolonged in renal impairment [34].
- **Clinical Implication:** Dose adjustment is required in patients with impaired renal function to prevent accumulation and toxicity [23], [25].
- **Clinical Interpretation:**
- Pharmacokinetics of acyclovir explain both its efficacy and potential for adverse effects. Intravenous therapy ensures therapeutic plasma concentrations in severe or CNS infections, while oral dosing suffices for uncomplicated mucocutaneous infections. **Renal monitoring** and dose adjustment are critical in elderly or renally impaired patients to prevent nephrotoxicity and neurotoxicity.

6. Drug–Drug Interactions

Acyclovir (ACV) has relatively few clinically significant drug–drug interactions due to its limited hepatic metabolism and predominant renal excretion. However, **concomitant medications affecting renal function or tubular secretion** can significantly alter its pharmacokinetics and increase the risk of adverse events.



6.1 Nephrotoxic Drugs

- **Aminoglycosides, Vancomycin, NSAIDs, Cisplatin:** Concurrent use with acyclovir may **increase the risk of nephrotoxicity** due to additive effects on renal tubular cells or reduced clearance [23], [34], [35].
- **Clinical Management:** Hydration, monitoring serum creatinine, and dose adjustment of acyclovir are recommended.

6.2 Drugs Affecting Renal Tubular Secretion

- **Probenecid:** Competes with acyclovir for renal tubular secretion, leading to **increased plasma levels** and potential toxicity [36].
- **Clinical Implication:** Monitor renal function, consider dose reduction if co-administered.

6.3 Other Potential Interactions

- **Mycophenolate Mofetil (MMF):** Limited data suggest slight reduction in MMF clearance when combined with ACV, possibly due to renal competition [37].
- **Zidovudine:** Rare cases report additive neurotoxicity in patients on high-dose IV acyclovir and antiretroviral therapy [38].

6.4 Clinical Interpretation

- Acyclovir's primary concern for interactions is **renal accumulation leading to nephrotoxicity and neurotoxicity**, rather than metabolic interactions. Clinicians should carefully review the patient's medication list, particularly **nephrotoxic or renally excreted drugs**, and adjust doses or monitor renal function as needed.

7. Special Populations

Acyclovir therapy requires careful consideration in **special populations**, including the elderly, pediatric patients, pregnant women, and immunocompromised individuals, due to differences in pharmacokinetics, susceptibility to adverse drug reactions (ADRs), and infection severity.

7.1 Elderly Patients

- **Pharmacokinetic Changes:** Age-related decline in renal function prolongs acyclovir half-life and increases plasma levels [34], [39].
- **Risk of ADRs:** Higher risk of nephrotoxicity and neurotoxicity, especially with intravenous therapy.
- **Clinical Considerations:** Dose adjustment based on creatinine clearance, careful hydration, and close monitoring of renal and neurological function are recommended.

7.2 Pediatric Patients

- **Neonates:** Immature renal function prolongs drug half-life. Intravenous acyclovir is critical for neonatal HSV infections, with dose adjustments based on weight and renal function [15], [40].
- **Older Children:** Oral therapy is generally safe; bioavailability is similar to adults.
- **Monitoring:** Serum creatinine and hydration status should be assessed, especially in infants receiving IV therapy.

7.3 Pregnant and Lactating Women

- **Safety Profile:** Oral acyclovir is generally considered safe in pregnancy (Category B, FDA), with no teratogenicity reported in human studies [41].
- **Clinical Considerations:** Treat active HSV infections promptly to reduce maternal and neonatal transmission. IV therapy may be indicated for severe maternal infections.
- **Lactation:** Acyclovir is excreted in breast milk at low concentrations. Breastfeeding is generally considered safe, but monitoring for infant gastrointestinal or neurological symptoms is advised [41], [42].

7.4 Immunocompromised Patients

- **Examples:** HIV/AIDS, transplant recipients, chemotherapy patients.
- **Clinical Challenges:** Higher risk of severe HSV or VZV infections, prolonged viral shedding, and acyclovir resistance [19], [20].
- **Management:** May require higher or prolonged doses of acyclovir, frequent monitoring for ADRs,



and vigilance for resistant strains. Prophylactic use is common to prevent viral reactivation.

Clinical Interpretation:
Special populations are at **increased risk of ADRs** and may require individualized dosing strategies. Pharmacovigilance in these groups is critical, emphasizing **renal monitoring, hydration, and early detection of neurotoxicity or hypersensitivity reactions**.

8. Comparative Safety

Acyclovir is widely regarded as a safe antiviral agent, but comparative analyses with other nucleoside analogues—such as **valacyclovir** and **famciclovir**—provide important insights into relative efficacy, pharmacokinetics, and adverse drug reaction (ADR) profiles.

8.1 Valacyclovir vs. Acyclovir

- **Pharmacokinetics:** Valacyclovir is a prodrug of acyclovir with significantly higher oral bioavailability (~55%) compared to oral acyclovir (~10–20%) [43]. This allows for less frequent dosing and better patient adherence.
- **Safety Profile:** Both drugs share similar ADR profiles, including renal and neurotoxicity. However, the lower dosing frequency of valacyclovir may reduce the risk of crystalluria and renal complications associated with peak plasma concentrations [43], [44].
- **Clinical Consideration:** In patients with adherence challenges or requiring long-term suppressive therapy, valacyclovir may be preferred without compromising safety.

8.2 Famciclovir vs. Acyclovir

- **Pharmacokinetics:** Famciclovir is a prodrug of penciclovir, orally absorbed with good bioavailability. Its plasma half-life allows for less frequent dosing compared to acyclovir [45].
- **Safety Profile:** ADRs are generally mild and comparable to acyclovir, primarily including headache, nausea, and gastrointestinal discomfort. Nephrotoxicity is rare due to renal-friendly dosing regimens [45].
- **Clinical Consideration:** Famciclovir may be preferred for adult shingles treatment where adherence and convenience are priorities, but cost may be higher than acyclovir.

8.3 Clinical Interpretation

- **Efficacy:** Acyclovir remains the standard therapy, particularly for **severe infections (e.g., HSV encephalitis, neonatal HSV, immunocompromised patients)** due to extensive clinical experience.
- **Safety:** Comparative studies indicate that acyclovir, valacyclovir, and famciclovir have similar ADR profiles, with differences largely related to pharmacokinetics and dosing convenience.
- **Pharmacovigilance Implications:** Clinicians should consider patient adherence, renal function, and risk of ADRs when selecting among these agents. Continuous monitoring for renal and neurological adverse events is recommended across all agents.

8. Comparative Safety

Acyclovir is widely regarded as a safe antiviral agent, but comparative analyses with other nucleoside analogues—such as **valacyclovir** and **famciclovir**—provide important insights into relative efficacy, pharmacokinetics, and adverse drug reaction (ADR) profiles.



8.1 Valacyclovir vs. Acyclovir

- **Pharmacokinetics:** Valacyclovir is a prodrug of acyclovir with significantly higher oral bioavailability (~55%) compared to oral acyclovir (~10–20%) [43]. This allows for less frequent dosing and better patient adherence.
- **Safety Profile:** Both drugs share similar ADR profiles, including renal and neurotoxicity. However, the lower dosing frequency of valacyclovir may reduce the risk of crystalluria and renal complications associated with peak plasma concentrations [43], [44].
- **Clinical Consideration:** In patients with adherence challenges or requiring long-term suppressive therapy, valacyclovir may be preferred without compromising safety.

8.2 Famciclovir vs. Acyclovir

- **Pharmacokinetics:** Famciclovir is a prodrug of penciclovir, orally absorbed with good bioavailability. Its plasma half-life allows for less frequent dosing compared to acyclovir [45].
- **Safety Profile:** ADRs are generally mild and comparable to acyclovir, primarily including headache, nausea, and gastrointestinal discomfort. Nephrotoxicity is rare due to renal-friendly dosing regimens [45].
- **Clinical Consideration:** Famciclovir may be preferred for adult shingles treatment where adherence and convenience are priorities, but cost may be higher than acyclovir.

8.3 Clinical Interpretation

- **Efficacy:** Acyclovir remains the standard therapy, particularly for **severe infections (e.g., HSV encephalitis, neonatal HSV, immunocompromised patients)** due to extensive clinical experience.
- **Safety:** Comparative studies indicate that acyclovir, valacyclovir, and famciclovir have similar ADR profiles, with differences largely related to pharmacokinetics and dosing convenience.
- **Pharmacovigilance Implications:** Clinicians should consider patient adherence, renal function, and risk of ADRs when selecting among these agents. Continuous monitoring for renal and neurological adverse events is recommended across all agents.

9. Pharmacovigilance Considerations

Pharmacovigilance (PV) plays a critical role in ensuring the **safe and effective use of acyclovir**. Continuous monitoring of adverse drug reactions (ADRs), resistance patterns, and drug interactions informs clinical decision-making and minimizes patient risk.

9.1 Post-Marketing Surveillance

- Acyclovir has been in clinical use for over four decades, and **post-marketing surveillance** has contributed significantly to identifying rare but serious ADRs, such as nephrotoxicity, neurotoxicity, and severe cutaneous reactions [22], [23], [25], [28].
- Spontaneous reporting systems (e.g., FDA Adverse Event Reporting System, WHO VigiBase) continue to monitor acyclovir safety, particularly in high-risk populations.

9.2 ADR Monitoring and Risk Mitigation

- **Renal Monitoring:** Serum creatinine, urine output, and hydration status should be assessed in patients receiving IV acyclovir or those with impaired renal function [23], [34].
- **Neurological Monitoring:** Elderly patients and those with renal impairment should be monitored for confusion, agitation, tremors, or seizures [25], [26].
- **Dermatologic and Hematologic Monitoring:** Prompt recognition of rashes, thrombocytopenia, or leukopenia is essential, especially in immunocompromised patients [27], [28].
- **Dose Adjustments:** Adjusting doses according to renal function reduces the risk of toxicity while maintaining therapeutic efficacy.

9.3 Resistance Surveillance

- PV systems track **emergence of acyclovir-resistant HSV/VZV strains**, which is particularly relevant in immunocompromised populations receiving long-term therapy [10], [19].

- Clinicians should report treatment failures or unusual adverse events to local PV centers to improve safety data collection and guide future recommendations.

9.4 Clinical Interpretation

Effective pharmacovigilance ensures that acyclovir therapy remains safe and effective. **Individualized dosing, proactive monitoring, and early detection of ADRs** are key components. For high-risk populations, integrating PV data into clinical practice reduces morbidity, prevents severe toxicity, and informs choice of alternative antiviral therapy when resistance or intolerance occurs.

9. Pharmacovigilance Considerations

Pharmacovigilance (PV) plays a critical role in ensuring the **safe and effective use of acyclovir**. Continuous monitoring of adverse drug reactions (ADRs), resistance patterns, and drug interactions informs clinical decision-making and minimizes patient risk.

9.1 Post-Marketing Surveillance

- Acyclovir has been in clinical use for over four decades, and **post-marketing surveillance** has contributed significantly to identifying rare but serious ADRs, such as nephrotoxicity, neurotoxicity, and severe cutaneous reactions [22], [23], [25], [28].
- Spontaneous reporting systems (e.g., FDA Adverse Event Reporting System, WHO VigiBase) continue to monitor acyclovir safety, particularly in high-risk populations.

9.2 ADR Monitoring and Risk Mitigation

- **Renal Monitoring:** Serum creatinine, urine output, and hydration status should be assessed in patients receiving IV acyclovir or those with impaired renal function [23], [34].



- **Neurological Monitoring:** Elderly patients and those with renal impairment should be monitored for confusion, agitation, tremors, or seizures [25], [26].
- **Dermatologic and Hematologic Monitoring:** Prompt recognition of rashes, thrombocytopenia, or leukopenia is essential, especially in immunocompromised patients [27], [28].
- **Dose Adjustments:** Adjusting doses according to renal function reduces the risk of toxicity while maintaining therapeutic efficacy.

9.3 Resistance Surveillance

- PV systems track **emergence of acyclovir-resistant HSV/VZV strains**, which is particularly relevant in immunocompromised populations receiving long-term therapy [10], [19].
- Clinicians should report treatment failures or unusual adverse events to local PV centers to improve safety data collection and guide future recommendations.

9.4 Clinical Interpretation

Effective pharmacovigilance ensures that acyclovir therapy remains safe and effective. **Individualized dosing, proactive monitoring, and early detection of ADRs** are key components. For high-risk populations, integrating PV data into clinical practice reduces morbidity, prevents severe toxicity, and informs choice of alternative antiviral therapy when resistance or intolerance occurs.

10. Conclusion

Acyclovir remains a **cornerstone antiviral therapy** for HSV and VZV infections due to its high efficacy, selectivity for infected cells, and overall favorable safety profile. Pharmacovigilance data accumulated over decades highlight that while acyclovir is generally well-tolerated, **specific populations—elderly, neonates, pregnant women, and immunocompromised patients—require careful monitoring** to prevent nephrotoxicity, neurotoxicity, and rare severe ADRs.

The drug's pharmacokinetics, including renal excretion and minimal hepatic metabolism, make **dose adjustment and hydration** essential in patients with impaired renal function. Resistance remains uncommon but should be considered in prolonged or recurrent therapy, particularly in immunocompromised hosts. Comparative safety analyses suggest that alternative antivirals like valacyclovir and famciclovir offer improved bioavailability or dosing convenience, but the **ADR profiles remain broadly similar**.

Clinical Implications:

- **Monitoring:** Renal function, neurological status, and hydration are critical during therapy, especially IV administration.
- **Risk Mitigation:** Pharmacovigilance ensures early identification of ADRs and resistance, guiding dose adjustment and therapeutic decisions.
- **Patient Safety:** Vigilant PV practices, individualized dosing, and adherence to clinical guidelines optimize outcomes across all patient populations.

In summary, acyclovir's **long-standing clinical use and extensive pharmacovigilance data** confirm its safety and efficacy while emphasizing the importance of monitoring high-risk patients to maintain favorable therapeutic outcomes.

REFERENCES:

[1] World Health Organization, Pharmacovigilance: ensuring the safe use of medicines, Geneva, 2002.
[2] R. M. Mayer et al., "Pharmacovigilance and adverse drug reaction reporting," Clin. Pharmacol. Ther., vol. 80, pp. 103–110, 2006.
[3] S. R. Krsmanovic, "Drug safety monitoring in clinical practice," Drug Saf., vol. 28, pp. 1041–1052, 2005.
[4] P. Aronson, "Pharmacovigilance: definitions, history and regulatory framework," Br. J. Clin. Pharmacol., vol. 63, pp. 139–148, 2007.

[5] M. Elion, “Mechanism of action and selectivity of acyclovir,” J. Antimicrob. Chemother., vol. 22, pp. 1–8, 1988.
[6] A. De Clercq, “Mechanisms of antiviral agents: selectivity and action,” Pharmacol. Ther., vol. 42, pp. 1–37, 1989.
[7] R. Whitley and J. Gnann, “Acyclovir: pharmacology and clinical use,” Drugs, vol. 43, pp. 150–185, 1992.
[8] S. Piret and G. Boivin, “Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management,” Antimicrob. Agents Chemother., vol. 55, no. 2, pp. 459–472, 2011.
[9] D. Wald et al., “Clinical relevance of acyclovir selectivity,” Clin. Infect. Dis., vol. 22, pp. S32–S38, 1996.
[10] P. Chou, “Mechanisms of acyclovir resistance in herpes simplex virus,” J. Infect. Dis., vol. 189, pp. S61–S68, 2004.
[11] J. Kimberlin and R. Whitley, “Antiviral therapy for herpesvirus infections in immunocompromised patients,” Lancet, vol. 354, pp. 188–194, 1999.
[12] R. Corey et al., “Acyclovir therapy for recurrent genital herpes: clinical efficacy and safety,” N. Engl. J. Med., vol. 318, pp. 678–682, 1988.
[13] D. Mertz et al., “Oral acyclovir for the treatment of recurrent herpes labialis,” J. Infect. Dis., vol. 168, pp. 1133–1139, 1993.
[14] R. Whitley et al., “Acyclovir therapy of herpes simplex virus encephalitis,” N. Engl. J. Med., vol. 314, pp. 144–149, 1986.
[15] C. Kimberlin, “Treatment of neonatal herpes simplex virus infections,” Pediatr. Infect. Dis. J., vol. 18, pp. 536–541, 1999.
[16] M. Dworkin et al., “Clinical evaluation of acyclovir in herpes zoster,” Arch. Intern. Med., vol. 154, pp. 1505–1510, 1994.
[17] J. Tyring et al., “Treatment of acute herpes zoster with oral acyclovir: effect on pain and lesion healing,” JAMA, vol. 269, pp. 1578–1583, 1993.
[18] H. Rubin et al., “Prophylactic acyclovir for prevention of varicella zoster in immunocompromised patients,” Clin. Infect. Dis., vol. 20, pp. 1490–1495, 1995.
[19] R. S. Hamilton et al., “Acyclovir therapy in immunocompromised hosts,” Clin. Infect. Dis., vol. 28, pp. 1166–1172, 1999.
[20] P. Lalezari et al., “Acyclovir prophylaxis in HIV-infected patients,” Ann. Intern. Med., vol. 112, pp. 146–150, 1990.
[21] C. Spruance et al., “Long-term suppressive acyclovir therapy in recurrent genital herpes,” J. Infect. Dis., vol. 158, pp. 997–1003, 1988.
[22] K. K. Schaefer et al., “Acyclovir nephrotoxicity: crystalluria and acute renal failure,” Am. J. Kidney Dis., vol. 9, pp. 370–374, 1987.
[23] J. W. Markowitz et al., “Renal toxicity associated with intravenous acyclovir,” Ann. Intern. Med., vol. 103, pp. 14–19, 1985.
[24] R. Whitley, “Prevention of acyclovir-induced nephrotoxicity,” Clin. Infect. Dis., vol. 22, pp. S39–S42, 1996.
[25] R. W. Kauffman et al., “Neurotoxicity associated with high-dose intravenous acyclovir,” Neurology, vol. 38, pp. 54–58, 1988.
[26] S. Aoki et al., “Acyclovir neurotoxicity in patients with renal impairment,” Clin. Nephrol., vol. 41, pp. 151–154, 1994.
[27] A. E. Spector et al., “Hematologic adverse effects of acyclovir,” Am. J. Hematol., vol. 31, pp. 105–108, 1989.
[28] M. Roujeau et al., “Severe cutaneous reactions to acyclovir: Stevens–Johnson syndrome and toxic epidermal necrolysis,” Arch. Dermatol., vol. 127, pp. 789–793, 1991.

[29] R. Corey et al., "Common adverse effects of oral acyclovir therapy," Clin. Infect. Dis., vol. 17, pp. 317–321, 1993.
[30] J. Boeckh et al., "Pharmacokinetics of oral acyclovir," Clin. Pharmacol. Ther., vol. 50, pp. 119–125, 1991.
[31] S. T. Tyring et al., "Distribution of acyclovir in body fluids and tissues," J. Infect. Dis., vol. 157, pp. 75–80, 1988.
[32] M. De Clercq, "Tissue penetration and protein binding of acyclovir," Antiviral Res., vol. 3, pp. 261–270, 1983.
[33] M. L. Perazella, "Metabolism of acyclovir and role of 9-carboxymethoxymethylguanine," Kidney Int., vol. 41, pp. 1015–1020, 1992.
[34] D. M. Brenner et al., "Renal clearance and pharmacokinetics of acyclovir in adults," Clin. Pharmacol. Ther., vol. 43, pp. 142–148, 1988.
[35] R. K. Andes et al., "Drug interactions and nephrotoxicity with acyclovir," Clin. Infect. Dis., vol. 20, pp. 113–117, 1995.
[36] J. Sweetman, Martindale: The Complete Drug Reference, 37th ed., London: Pharmaceutical Press, 2011.
[37] M. H. Hirsch et al., "Potential drug interactions with acyclovir in transplant patients," Transplantation, vol. 65, pp. 123–128, 1998.
[38] T. P. Sheppard et al., "Neurotoxicity with acyclovir and antiretroviral therapy," AIDS, vol. 9, pp. 707–709, 1995.
[39] M. N. Koren et al., "Pharmacokinetics of acyclovir in elderly patients," Clin. Pharmacokinet., vol. 23, pp. 386–392, 1992.
[40] C. Kimberlin, "Neonatal pharmacokinetics of acyclovir," Pediatr. Infect. Dis. J., vol. 18, pp. 536–541, 1999.
[41] S. S. Kimberlin et al., "Acyclovir therapy during pregnancy: safety and efficacy," Clin. Infect. Dis., vol. 32, pp. 100–106, 2001.
[42] R. R. Hitti et al., "Acyclovir excretion in breast milk," Am. J. Obstet. Gynecol., vol. 165, pp. 974–978, 1991.
[43] P. Tyring et al., "Valacyclovir: improved oral bioavailability compared to acyclovir," J. Antimicrob. Chemother., vol. 33, pp. 217–222, 1994.
[44] A. De Clercq, "Safety profile of valacyclovir vs. acyclovir," Antiviral Res., vol. 71, pp. 181–190, 2006.
[45] R. D. Spruance et al., "Famciclovir pharmacokinetics and safety," Clin. Infect. Dis., vol. 23, pp. 501–507, 1996.